Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth AssureMDx for Bladder Cancer Liquid Biopsy Test

MDxHealth has launched its AssureMDx for Bladder Cancer liquid biopsy test in the US as a laboratory-developed test. AssureMDx is a non-invasive, urine-based test. It searches for methylation and mutation biomarkers in order to assess the risk of bladder cancer for patients diagnosed with hematuria. The test's 93 percent sensitivity and 85 percent specificity can help doctors identify patients at increased risk for bladder cancer, who may benefit from cystoscopy, the company said. Testing will be conducted at MDxHealth's CAP- and CLIA-accredited lab in Irvine, California.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.